Резолюция экспертного совещания по использованию эритропоэзстимулирующих препаратов в онкологии от 3 ноября 2007 г.

1. Ludwig H., Van Bells S., Barret-Lee P. et al The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293—306.

2. Groopman J.L., Itri L.M. Chemotherapy induced anemia in adults: incidence and treatment. JNCI 1999;91:1616—34.

3. Lefebvre P., Vecerman F., Sarokham B. et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin. Cur Med Res Opin 2006;22:1929—37.

4. Brizel D.M., Sibley G.S., Prosnitz L.R. et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285—9.

5. Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214—21.

6. Dzik W.H. Emily Cooley Lecture 2002: transfusion safety in the hospital. Transfusion 2003;43:1190—9.

7. Blajchman M.A., Vamvakas E.C. The Continuing Risk of Transfusion-Transmitted Infections. NEJM 2006;355:1303—5.

8. Bolhius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708—14. Review